Search

Your search keyword '"Zile, Michael R"' showing total 112 results
Start Over Author "Zile, Michael R" Publisher wiley
112 results on '"Zile, Michael R"'

1. In vivo fluid dynamics of the Ventura interatrial shunt device in patients with heart failure

Author

Pfeiffer, Michael, primary, Boehmer, John, additional, Gorcsan, John, additional, Eguchi, Shunsuke, additional, Orihara, Yoshiyuki, additional, Perl, Michal Laufer, additional, Eigler, Neal, additional, Abraham, William T., additional, Villota, Julio Nuñez, additional, Lee, Elizabeth, additional, Bayés‐Genís, Antoni, additional, Moravsky, Gil, additional, Kar, Saibal, additional, Zile, Michael R., additional, Holcomb, Richard, additional, Anker, Stefan D., additional, Stone, Gregg W., additional, Rodés‐Cabau, Josep, additional, Lindenfeld, JoAnn, additional, and Bax, Jeroen J., additional

Published
2024
Full Text
View/download PDF

3. Interatrial shunt therapy in advanced heart failure: Outcomes from the open‐label cohort of the RELIEVE‐HF trial

Author

Rodés‐Cabau, Josep, primary, Lindenfeld, JoAnn, additional, Abraham, William T., additional, Zile, Michael R., additional, Kar, Saibal, additional, Bayés‐Genís, Antoni, additional, Eigler, Neal, additional, Holcomb, Richard, additional, Núñez, Julio, additional, Lee, Elizabeth, additional, Perl, Michal Laufer, additional, Moravsky, Gil, additional, Pfeiffer, Michael, additional, Boehmer, John, additional, Gorcsan, John, additional, Bax, Jeroen J., additional, Anker, Stefan, additional, and Stone, Gregg W., additional

Published
2024
Full Text
View/download PDF

4. Clinical implications of subclinical left ventricular dysfunction in heart failure with preserved ejection fraction: The PARAGON‐HF study

Author

Minamisawa, Masatoshi, primary, Inciardi, Riccardo M., additional, Claggett, Brian, additional, Cikes, Maja, additional, Liu, Li, additional, Prasad, Narayana, additional, Biering‐Sørensen, Tor, additional, Lam, Carolyn S.P., additional, Shah, Sanjiv J., additional, Zile, Michael R., additional, O'Meara, Eileen, additional, Redfield, Margaret M., additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Shah, Amil M., additional

Published
2024
Full Text
View/download PDF

5. Independent prognostic importance of blood urea nitrogen (BUN) to creatinine ratio in heart failure

Author

Tolomeo, Paolo, primary, Butt, Jawad H, additional, Kondo, Toru, additional, Campo, Gianluca, additional, Desai, Akshay S., additional, Jhund, Pardeep S, additional, Køber, Lars, additional, Lefkowitz, Martin P., additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Swedberg, Karl, additional, Vaduganathan, Muthiah, additional, Zile, Michael R., additional, Packer, Milton, additional, and McMurray, John JV, additional

Published
2023
Full Text
View/download PDF

6. Heart failure with preserved ejection fraction, red cell distribution width, and sacubitril/valsartan

Author

Butt, Jawad H., primary, McDowell, Kirsty, additional, Kondo, Toru, additional, Desai, Akshay S., additional, Lefkowitz, Martin P., additional, Packer, Milton, additional, Petrie, Mark C., additional, Pfeffer, Marc A., additional, Rouleau, Jean L., additional, Vaduganathan, Muthiah, additional, Zile, Michael R., additional, Jhund, Pardeep S., additional, Køber, Lars, additional, Solomon, Scott, additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

7. Calcium channel blocker and outcomes in patients with heart failure and mildly reduced and preserved ejection fraction

Author

Matsumoto, Shingo, primary, Kondo, Toru, additional, Yang, Mingming, additional, Campbell, Ross T, additional, Docherty, Kieran F., additional, de Boer, Rudolf A., additional, Desai, Akshay S., additional, Lam, Carolyn S.P., additional, Packer, Milton, additional, Pitt, Bertram, additional, Rouleau, Jean L., additional, Vaduganathan, Muthiah, additional, Zannad, Faiez, additional, Zile, Michael R., additional, Solomon, Scott D., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

8. Knowledge about self‐efficacy and outcomes in patients with heart failure and reduced ejection fraction

Author

Yang, Mingming, primary, Kondo, Toru, additional, Adamson, Carly, additional, Butt, Jawad H., additional, Abraham, William T., additional, Desai, Akshay S., additional, Jering, Karola S., additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Packer, Milton, additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Vaduganathan, Muthiah, additional, Zile, Michael R., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

9. Changes in mid‐regional pro‐adrenomedullin during treatment with sacubitril/valsartan

Author

Myhre, Peder L., primary, Liu, Yuxi, additional, Kulac, Ian J., additional, Claggett, Brian L., additional, Prescott, Margaret F., additional, Felker, G. Michael, additional, Butler, Javed, additional, Piña, Ileana L., additional, Rouleau, Jean L., additional, Zile, Michael R., additional, McMurray, John J.V., additional, Ward, Jonathan H., additional, Solomon, Scott D., additional, and Januzzi, James L., additional

Published
2023
Full Text
View/download PDF

10. Impact of comorbidities on health status measured using the Kansas City Cardiomyopathy Questionnaire in patients with HFrEF and HFpEF

Author

Yang, Mingming, primary, Kondo, Toru, additional, Adamson, Carly, additional, Butt, Jawad H., additional, Abraham, William T., additional, Desai, Akshay S., additional, Jering, Karola S., additional, Køber, Lars, additional, Kosiborod, Mikhail N., additional, Packer, Milton, additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Vaduganathan, Muthiah, additional, Zile, Michael R., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

11. Clinical characteristics of HFrEF patients with rare pathogenic variants in DCM ‐associated genes: a subgroup analysis of the PARADIGM‐HF trial

Author

Barat, Ana, primary, Chen, Chien‐Wei, additional, Patel‐Murray, Natasha, additional, McMurray, John J.V., additional, Packer, Milton, additional, Solomon, Scott D., additional, Desai, Akshay S., additional, Rouleau, Jean L., additional, Zile, Michael R., additional, Attari, Zenab, additional, Zhang, Cong, additional, Xu, Huilei, additional, Hartman, Nicole, additional, Hon, Claudia, additional, Healey, Margaret, additional, Chutkow, William, additional, O'Donnell, Christopher J., additional, Jacob, Jaison, additional, Lefkowitz, Marty, additional, Mendelson, Michael M., additional, Wandel, Simon, additional, Yates, Denise, additional, and Gimpelewicz, Claudio, additional

Published
2023
Full Text
View/download PDF

12. Incremental prognostic value of biomarkers in PARADIGM‐HF

Author

McDowell, Kirsty, primary, Campbell, Ross, additional, Simpson, Joanne, additional, Cunningham, Jonathan W., additional, Desai, Akshay S., additional, Jhund, Pardeep S, additional, Lefkowitz, Martin P., additional, Rouleau, Jean L., additional, Swedberg, Karl, additional, Zile, Michael R., additional, Solomon, Scott D., additional, Packer, Milton, additional, and McMurray, John J.V., additional

Published
2023
Full Text
View/download PDF

13. Health‐related quality of life outcomes in PARAGON‐HF

Author

Chandra, Alvin, primary, Polanczyk, Carisi A., additional, Claggett, Brian L., additional, Vaduganathan, Muthiah, additional, Packer, Milton, additional, Lefkowitz, Martin P., additional, Rouleau, Jean L., additional, Liu, Jiankang, additional, Shi, Victor C., additional, Schwende, Heike, additional, Zile, Michael R., additional, Desai, Akshay S., additional, Pfeffer, Marc A., additional, McMurray, John J.V., additional, Solomon, Scott D., additional, and Lewis, Eldrin F., additional

Published
2022
Full Text
View/download PDF

14. Baroreflex activation therapy with the Barostim™ device in patients with heart failure with reduced ejection fraction: a patient level meta‐analysis of randomized controlled trials

Author

Coats, Andrew J.S., primary, Abraham, William T., additional, Zile, Michael R., additional, Lindenfeld, Joann A., additional, Weaver, Fred A., additional, Fudim, Marat, additional, Bauersachs, Johann, additional, Duval, Sue, additional, Galle, Elizabeth, additional, and Zannad, Faiez, additional

Published
2022
Full Text
View/download PDF

15. Diabetes and pre‐diabetes in patients with heart failure and preserved ejection fraction

Author

Jackson, Alice M., Rørth, Rasmus, Liu, Jiankang, Kristensen, Søren Lund, Anand, Inder S., Claggett, Brian L., Cleland, John G.F., Chopra, Vijay K., Desai, Akshay S., Ge, Junbo, Gong, Jianjian, Lam, Carolyn S.P., Lefkowitz, Martin P., Maggioni, Aldo P., Martinez, Felipe, Packer, Milton, Pfeffer, Marc A., Pieske, Burkert, Redfield, Margaret M., Rizkala, Adel R., Rouleau, Jean L., Seferović, Petar M., Tromp, Jasper, Van Veldhuisen, Dirk J., Yilmaz, Mehmet B., Zannad, Faiez, Zile, Michael R., Køber, Lars, Petrie, Mark C., Jhund, Pardeep S., Solomon, Scott D., and McMurray, John J.V.

Subjects
R1
Abstract

Aim:\ud There is an association between heart failure with preserved ejection fraction (HFpEF) and insulin resistance, but less is known about the diabetic continuum, and in particular about pre-diabetes, in HFpEF. We examined characteristics and outcomes of participants with diabetes or pre-diabetes in PARAGON-HF.\ud \ud Methods and results:\ud Patients aged ≥50 years with left ventricular ejection fraction ≥45%, structural heart disease and elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) were eligible. Patients were classified according to glycated haemoglobin (HbA1c): (i) normal HbA1c

Published
2022

16. Effect of sacubitril/valsartan on investigator-reported ventricular arrhythmias in PARADIGM-HF

Author

Curtain, James P., Jackson, Alice, Shen, Li, Jhund, Pardeep S., Docherty, Kieran F., Petrie, Mark C., Castagno, Davide, Desai, Akshay S., Rohde, Luis E., Lefkowitz, Martin P., Rouleau, Jean-Lucien, Zile, Michael R., Solomon, Scott D., Swedberg, Karl, Packer, Milton, and McMurray, John J.V.

Subjects
cardiovascular system, cardiovascular diseases
Abstract

Background:\ud Sudden death is a leading cause of mortality in HFrEF. In PARADIGM-HF, sacubitril/valsartan reduced the incidence of sudden death. The purpose of this post hoc study was to analyze the effect of sacubitril/valsartan, compared to enalapril, on the incidence of ventricular arrhythmias.\ud \ud Methods:\ud Adverse event reports related to ventricular arrhythmias were examined in PARADIGM-HF. The effect of randomized treatment on two arrhythmia outcomes was analyzed: ventricular arrhythmias and the composite of a ventricular arrhythmia, ICD shock or resuscitated cardiac arrest. The risk of death related to a ventricular arrhythmia was examined in time-updated models. The interaction between heart failure aetiology, or baseline ICD/CRT-D use, and the effect of sacubitril/valsartan was analyzed.\ud \ud Results:\ud Of the 8399 participants, 333 (4.0%) reported a ventricular arrhythmia and 372 (4.4%) the composite arrhythmia outcome. Ventricular arrhythmias were associated with higher mortality. Compared with enalapril, sacubitril/valsartan reduced the risk of a ventricular arrhythmia [HR 0.76 (0.62–0.95); p = 0.015] and the composite arrhythmia outcome [HR 0.79 (0.65–0.97); p = 0.025]. The treatment effect was maintained after adjustment and accounting for the competing risk of death. Baseline ICD/CRT-D use did not modify effect of sacubitril/valsartan, but aetiology did: HR in patients with an ischaemic aetiology 0.93 (0.71–1.21) versus 0.53 (0.37–0.78) in those without an ischaemic aetiology (p for interaction = 0.020).\ud \ud Conclusions:\ud Sacubitril/valsartan reduced the incidence of investigator-reported ventricular arrhythmias in patients with HFrEF. This effect may have been greater in patients with a non-ischaemic aetiology.

Published
2022

17. Influence of study discontinuation during the run‐in period on the estimated efficacy of sacubitril/valsartan in the PARAGON‐HF trial

Author

Suzuki, Kota, Claggett, Brian, Minamisawa, Masatoshi, Packer, Milton, Zile, Michael R., Pfeffer, Marc A., Chiang, Lu‐May, Lefkowitz, Martin, McMurray, John J.V., Solomon, Scott D., and Desai, Akshay S.

Abstract

Aims: \ud The 4822 patients randomized in the PARAGON-HF trial were a subset of 5746 initially eligible patients who entered sequential run-in periods. We identified patient factors associated with study discontinuation during the run-in period and estimated the implications of these discontinuations for the overall study result.\ud \ud Methods and Results: \ud We utilized multivariable logistic regression models to identify patient factors associated with study discontinuation during the run-in. The efficacy of sacubitril/valsartan in a broader cohort approximating the full run-in population was estimated by weighting randomized patients according to the inverse probability of run-in completion. A total of 924 (16.1%) subjects failed to complete the run-in period. In multivariable models, noncompletion was associated with region other than Central Europe, lower systolic blood pressure, lower serum sodium, lower hemoglobin, lower estimated glomerular filtration rate, higher NT-proBNP, higher NYHA functional class, prior HF hospitalization, and lack of prior use of renin-angiotensin system inhibitors or beta-blocker. In repeat analysis of the effect of randomized treatment in PARAGON-HF giving greater weight to participants resembling those who failed to complete the run-in period, the incidence of HF hospitalizations and cardiovascular death was higher, and sacubitril/valsartan treatment reduced the composite of total HF hospitalizations and cardiovascular death compared with valsartan (rate ratio, 0.86; 95% confidence interval, 0.74–1.00).\ud \ud Conclusion: \ud Patients with more advanced heart failure were at higher risk for noncompletion of the run-in period in PARAGON-HF. Reanalysis of study outcomes accounting for the effect of run-in noncompletion did not alter the estimated treatment effects of sacubitril/valsartan vs valsartan.

Published
2021

18. Effect of sacubitril/valsartan versus enalapril on changes in heart failure therapies over time: the PARADIGM‐HF trial

Author

Bhatt, Ankeet S., Vaduganathan, Muthiah, Claggett, Brian L., Liu, Jiankang, Packer, Milton, Desai, Akshay S., Lefkowitz, Martin P., Rouleau, Jean L., Shi, Victor C., Zile, Michael R., Swedberg, Karl, Vardeny, Orly, McMurray, John J.V., and Solomon, Scott D.

Subjects
cardiovascular diseases, circulatory and respiratory physiology
Abstract

Background: \ud Sacubitril/valsartan improves morbidity and mortality in patients with heart failure and reduced ejection fraction (HFrEF). Whether initiation of sacubitril/valsartan limits the use and dosing of other elements of guideline-directed medical therapy (GDMT) for HFrEF is unknown. We examined the effects of sacubitril/valsartan, compared with enalapril, on β-blocker and MRA use and dosing in a large randomized clinical trial.\ud \ud Methods: \ud Patients with full data on medication/dose use were included. We examined β-blocker and MRA use/dose in patients randomized to sacubitril/valsartan versus enalapril through 12-month follow-up. New initiations and discontinuations of β-blocker and MRA were compared between treatment groups.\ud \ud Results: \ud Overall, 8398 (99.9%) had full medication and dose data at baseline. Baseline use of β-blocker and MRA at any dose was 87.1% and 55%, respectively. Mean doses of β-blocker and MRA were similar between treatment groups at baseline and at 6-months and 12-months follow-up. New initiations through 12-months follow-up were infrequent and similar in the sacubitril/valsartan and enalapril groups for β-blockers (37 [9.0%] vs. 42 [10.2%], p = 0.56) and MRA (127 [7.6%] vs. 143 [9.2%], p = 0.10). Among patients on MRA therapy at baseline (n = 4634), there were fewer MRA discontinuations in patients on sacubitril/valsartan as compared with enalapril at 12-months (125 [6.2%] vs. 187 [9.0%], p = 0.001). Discontinuations of β-blockers were not significantly different between groups in follow-up (2.2% vs 2.6%, p = 0.26).\ud \ud Conclusions: \ud Initiation of sacubitril/valsartan, even when titrated to target dose, did not appear to lead to greater discontinuation or dose downtitrations of other key guideline-directed medical therapies, and was associated with fewer discontinuations of MRA. Use of sacubitril/valsartan (when compared with enalapril) may promote sustained MRA use in follow-up.

Published
2021

19. Prevalence and incidence of intra-ventricular conduction delays and outcomes in patients with heart failure and reduced ejection fraction: insights from PARADIGM‐HF and ATMOSPHERE

Author

Kristensen, Søren Lund, Castagno, Davide, Shen, Li, Jhund, Pardeep, Docherty, Kieran, Rørth, Rasmus, Abraham, William T., Desai, Akshay, Dickstein, Kenneth, Rouleau, Jean L., Zile, Michael R., Swedberg, Karl, Packer, Milton, Solomon, Scott D., Køber, Lars, and McMurray, John J.V.

Abstract

Aims: The importance of intraventricular conduction delay (IVCD), incidence of new IVCD and its relationship to outcomes in heart failure and reduced ejection fraction (HFrEF) is not well studied. We addressed these questions in the PARADIGM-HF and ATMOSPHERE trials.\ud \ud Methods and results: Risk of the primary composite outcome of cardiovascular death or HF hospitalization and all-cause mortality were estimated by use of Cox regression according to baseline QRS duration and morphology in 11,861 patients without an intracardiac device. At baseline, 1,789 (15.1%) patients had left bundle branch block (LBBB), 524 (4.4%) RBBB, 454 (3.8%) non-specific IVCD, 2588 (21.8%) "mildly abnormal" QRS (110-129 milliseconds [ms]) and 6506 (54.9%) QRS

Published
2020

20. Serum potassium and outcomes in heart failure with preserved ejection fraction: a post‐hoc analysis of the PARAGON‐HF trial

Author

Ferreira, João Pedro, primary, Claggett, Brian L., additional, Liu, Jiankang, additional, Desai, Akshay S., additional, Pfeffer, Marc A., additional, Anand, Inder S., additional, van Veldhuisen, Dirk J., additional, Kober, Lars, additional, Cleland, John G.F., additional, Rouleau, Jean L., additional, Packer, Milton, additional, Zile, Michael R., additional, Shi, Victor C., additional, Lefkowitz, Martin P., additional, Shah, Sanjiv J., additional, Vardeny, Orly, additional, Zannad, Faiez, additional, Solomon, Scott D., additional, and McMurray, John J.V., additional

Published
2021
Full Text
View/download PDF

21. Serum potassium in the PARADIGM-HF trial

Author

Ferreira, João Pedro, Mogensen, Ulrik M., Jhund, Pardeep S., Desai, Akshay S., Zile, Michael R., Rossignol, Patrick, Zannad, Faiez, Packer, Milton, Solomon, Scott D., and McMurray, John J.V.

Abstract

Aims: \ud The associations between potassium level and outcomes, the effect of sacubitril–valsartan on potassium level, and whether potassium level modified the effect of sacubitril–valsartan in patients with heart failure and a reduced ejection fraction were studied in PARADIGM‐HF. Several outcomes, including cardiovascular death, sudden death, pump failure death, non‐cardiovascular death and heart failure hospitalization, were examined.\ud \ud Methods and results: \ud A total of 8399 patients were randomized to either enalapril or sacubitril–valsartan. Potassium level at randomization and follow‐up was examined as a continuous and categorical variable (≤3.5, 3.6–4.0, 4.1–4.9, 5.0–5.4 and ≥5.5 mmol/L) in various statistical models. Hyperkalaemia was defined as K+ ≥5.5 mmol/L and hypokalaemia as K+ ≤3.5 mmol/L. Compared with potassium 4.1–4.9 mmol/L, both hypokalaemia [hazard ratio (HR) 2.40, 95% confidence interval (CI) 1.84–3.14] and hyperkalaemia (HR 1.42, 95% CI 1.10–1.83) were associated with a higher risk for cardiovascular death. However, potassium abnormalities were similarly associated with sudden death and pump failure death, as well as non‐cardiovascular death and heart failure hospitalization. Sacubitril–valsartan had no effect on potassium overall. The benefit of sacubitril–valsartan over enalapril was consistent across the range of baseline potassium levels.\ud \ud Conclusions: \ud Although both higher and lower potassium levels were independent predictors of cardiovascular death, potassium abnormalities may mainly be markers rather than mediators of risk for death.

Published
2020

22. INTERVENE‐HF: feasibility study of individualized, risk stratification‐based, medication intervention in patients with heart failure with reduced ejection fraction

Author

Zile, Michael R., primary, Costanzo, Maria Rosa R., additional, Ippolito, Ekaterina M., additional, Zhang, Yan, additional, Stapleton, Russell, additional, Sadhu, Ashish, additional, Jimenez, Javier, additional, Hobbs, Joe, additional, Sharma, Vinod, additional, Warman, Eduardo N., additional, Streeter, Lindsay, additional, and Butler, Javed, additional

Published
2021
Full Text
View/download PDF

24. Impact of diabetes on serum biomarkers in heart failure with preserved ejection fraction: insights from the TOPCAT trial

Author

De Marco, Corrado, primary, Claggett, Brian L., additional, Denus, Simon, additional, Zile, Michael R., additional, Huynh, Thao, additional, Desai, Akshay S., additional, Sirois, Martin G., additional, Solomon, Scott D., additional, Pitt, Bertram, additional, Rouleau, Jean L., additional, Pfeffer, Marc A., additional, and O'Meara, Eileen, additional

Published
2021
Full Text
View/download PDF

26. Relationship between duration of heart failure, patient characteristics, outcomes, and effect of therapy in PARADIGM‐HF

Author

Yeoh, Su E., primary, Dewan, Pooja, additional, Desai, Akshay S., additional, Solomon, Scott D., additional, Rouleau, Jean L., additional, Lefkowitz, Marty, additional, Rizkala, Adel, additional, Swedberg, Karl, additional, Zile, Michael R., additional, Jhund, Pardeep S., additional, Packer, Milton, additional, and McMurray, John J.V., additional

Published
2020
Full Text
View/download PDF

27. Serum uric acid, influence of sacubitril–valsartan, and cardiovascular outcomes in heart failure with preserved ejection fraction: PARAGON‐HF

Author

Selvaraj, Senthil, primary, Claggett, Brian L., additional, Pfeffer, Marc A., additional, Desai, Akshay S., additional, Mc Causland, Finnian R., additional, McGrath, Martina M., additional, Anand, Inder S., additional, Veldhuisen, Dirk J., additional, Kober, Lars, additional, Janssens, Stefan, additional, Cleland, John G.F., additional, Pieske, Burkert, additional, Rouleau, Jean L., additional, Zile, Michael R., additional, Shi, Victor C., additional, Lefkowitz, Martin P., additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2020
Full Text
View/download PDF

30. Liver function and prognosis, and influence of sacubitril/valsartan in patients with heart failure with reduced ejection fraction

Author

Suzuki, Kota, primary, Claggett, Brian, additional, Minamisawa, Masatoshi, additional, Packer, Milton, additional, Zile, Michael R., additional, Rouleau, Jean, additional, Swedberg, Karl, additional, Lefkowitz, Martin, additional, Shi, Victor, additional, McMurray, John J.V., additional, Zucker, Stephen D., additional, and Solomon, Scott D., additional

Published
2020
Full Text
View/download PDF

31. The prevalence and importance of frailty in heart failure with reduced ejection fraction – an analysis of PARADIGM‐HF and ATMOSPHERE

Author

Dewan, Pooja, primary, Jackson, Alice, additional, Jhund, Pardeep S., additional, Shen, Li, additional, Ferreira, João Pedro, additional, Petrie, Mark C., additional, Abraham, William T., additional, Desai, Akshay S., additional, Dickstein, Kenneth, additional, Køber, Lars, additional, Packer, Milton, additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Swedberg, Karl, additional, Zile, Michael R., additional, and McMurray, John J.V., additional

Published
2020
Full Text
View/download PDF

32. Relationship between heart rate and outcomes in patients in sinus rhythm or atrial fibrillation with heart failure and reduced ejection fraction

Author

Docherty, Kieran F., primary, Shen, Li, additional, Castagno, Davide, additional, Petrie, Mark C., additional, Abraham, William T., additional, Böhm, Michael, additional, Desai, Akshay S., additional, Dickstein, Kenneth, additional, Køber, Lars V., additional, Packer, Milton, additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Swedberg, Karl, additional, Vazir, Ali, additional, Zile, Michael R., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2019
Full Text
View/download PDF

33. The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes

Author

Rørth, Rasmus, Jhund, Pardeep S., Kristensen, Søren Lund, Desai, Akshay S., Køber, Lars, Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R., Packer, Milton, and McMurray, John J.V.

Subjects
cardiovascular diseases, musculoskeletal system, hormones, hormone substitutes, and hormone antagonists
Abstract

Aims:\ud \ud We examined the prognostic importance of N‐terminal pro B‐type natriuretic peptide (NT‐proBNP) and troponin T (TnT) in heart failure patients with and without diabetes.\ud Methods and results:\ud \ud We measured NT‐proBNP and TnT in the biomarker substudy of the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure trial (PARADIGM‐HF). Of 1907 patients, 759 (40%) had diabetes. Median TnT in patients with diabetes was 18 (interquartile range 11–27) ng/L and 13 (9–21) ng/L in those without (P

Published
2019

34. Post hoc analyses of SHIFT and PARADIGM-HF highlight the importance of chronic Chagas' cardiomyopathy Comment on: 'Safety profile and efficacy of ivabradine in heart failure due to Chagas heart disease: a post hoc analysis of the SHIFT trial' by Bocchi et al

Author

Ramires, Felix J.A., Martinez, Felipe, Gómez, Efraín A., Demacq, Caroline, Gimpelewicz, Claudio R., Rouleau, Jean L., Solomon, Scott D., Swedberg, Karl, Zile, Michael R., Packer, Milton, and McMurray, John J.V.

Abstract

No abstract available.

Published
2018

35. Insulin treatment and clinical outcomes in patients with diabetes and heart failure with preserved ejection fraction

Author

Shen, Li, primary, Rørth, Rasmus, additional, Cosmi, Deborah, additional, Kristensen, Søren Lund, additional, Petrie, Mark C., additional, Cosmi, Franco, additional, Latini, Roberto, additional, Køber, Lars, additional, Anand, Inder S., additional, Carson, Peter E., additional, Granger, Christopher B., additional, Komajda, Michel, additional, McKelvie, Robert S., additional, Solomon, Scott D., additional, Staszewsky, Lidia, additional, Swedberg, Karl, additional, Huynh, Thao, additional, Zile, Michael R., additional, Jhund, Pardeep S., additional, and McMurray, John J.V., additional

Published
2019
Full Text
View/download PDF

36. Reduced loop diuretic use in patients taking sacubitril/valsartan compared with enalapril: the PARADIGM‐HF trial

Author

Vardeny, Orly, primary, Claggett, Brian, additional, Kachadourian, Jessica, additional, Desai, Akshay S., additional, Packer, Milton, additional, Rouleau, Jean, additional, Zile, Michael R., additional, Swedberg, Karl, additional, Lefkowitz, Martin, additional, Shi, Victor, additional, McMurray, John J.V., additional, and Solomon, Scott D., additional

Published
2019
Full Text
View/download PDF

37. The prognostic value of troponin T and N‐terminal pro B‐type natriuretic peptide, alone and in combination, in heart failure patients with and without diabetes

Author

Rørth, Rasmus, primary, Jhund, Pardeep S., additional, Kristensen, Søren L., additional, Desai, Akshay S., additional, Køber, Lars, additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Swedberg, Karl, additional, Zile, Michael R., additional, Packer, Milton, additional, and McMurray, John J.V., additional

Published
2018
Full Text
View/download PDF

38. Heart failure with reduced ejection fraction: comparison of patient characteristics and clinical outcomes within Asia and between Asia, Europe and the Americas

Author

Dewan, Pooja, primary, Jhund, Pardeep S., additional, Shen, Li, additional, Petrie, Mark C., additional, Abraham, William T., additional, Atif Ali, M., additional, Chen, Chen‐Huan, additional, Desai, Akshay S., additional, Dickstein, Kenneth, additional, Huang, Jun, additional, Kiatchoosakun, Songsak, additional, Kim, Kee‐Sik, additional, Køber, Lars, additional, Lai, Wen‐Ter, additional, Liao, Yuhua, additional, Mogensen, Ulrik M., additional, Oh, Byung‐Hee, additional, Packer, Milton, additional, Rouleau, Jean L., additional, Shi, Victor, additional, Sibulo, Antonio S., additional, Solomon, Scott D., additional, Sritara, Piyamitr, additional, Swedberg, Karl, additional, Tsutsui, Hiroyuki, additional, Zile, Michael R., additional, and McMurray, John J.V., additional

Published
2018
Full Text
View/download PDF

39. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM‐HF)

Author

Mogensen, Ulrik M., primary, Gong, Jianjian, additional, Jhund, Pardeep S., additional, Shen, Li, additional, Køber, Lars, additional, Desai, Akshay S., additional, Lefkowitz, Martin P., additional, Packer, Milton, additional, Rouleau, Jean L., additional, Solomon, Scott D., additional, Claggett, Brian L., additional, Swedberg, Karl, additional, Zile, Michael R., additional, Mueller‐Velten, Guenther, additional, and McMurray, John J.V., additional

Published
2018
Full Text
View/download PDF

41. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy

Author

Zile, Michael R., Abraham, William T., Weaver, Fred A., Butter, Christian, Ducharme, Anique, Halbach, Marcel, Klug, Didier, Lovett, Eric G., Mueller-Ehmsen, Jochen, Schafer, Jill E., Senni, Michele, Swarup, Vijay, Wachter, Rolf, Little, William C., Zile, Michael R., Abraham, William T., Weaver, Fred A., Butter, Christian, Ducharme, Anique, Halbach, Marcel, Klug, Didier, Lovett, Eric G., Mueller-Ehmsen, Jochen, Schafer, Jill E., Senni, Michele, Swarup, Vijay, Wachter, Rolf, and Little, William C.

Abstract

AimsIncreased sympathetic and decreased parasympathetic activity contribute to heart failure (HF) symptoms and disease progression. Carotid baroreceptor stimulation (baroreflex activation therapy, BAT) results in centrally mediated reduction of sympathetic and increase in parasympathetic activity. Because patients treated with cardiac resynchronization therapy (CRT) may have less sympathetic/parasympathetic imbalance, we hypothesized that there would be differences in the response to BAT in patients with CRT vs. those without CRT. Methods and resultsNew York Heart Association (NYHA) Class III patients with an ejection fraction (EF) 35% were randomized (1 : 1) to ongoing guideline-directed medical and device therapy (GDMT, control) or ongoing GDMT plus BAT. Safety endpoint was system-/procedure-related major adverse neurological and cardiovascular events (MANCE). Efficacy endpoints were Minnesota Living with Heart Failure Quality of Life (QoL), 6-min hall walk distance (6MHWD), N-terminal pro-brain natriuretic peptide (NT-proBNP), left ventricular ejection fraction (LVEF), and HF hospitalization rate. In this sample, 146 patients were randomized (70 control; 76 BAT) and were 140 activated (45 with CRT and 95 without CRT). MANCE-free rate at 6 months was 100% in CRT and 96% in no-CRT group. At 6 months, in the no-CRT group, QoL score, 6MHWD, LVEF, NT-proBNP and HF hospitalizations were significantly improved in BAT patients compared with controls. Changes in efficacy endpoints in the CRT group favoured BAT; however, the improvements were less than in the no-CRT group and were not statistically different from control. ConclusionsBAT is safe and significantly improved QoL, exercise capacity, NTpro-BNP, EF, and rate of HF hospitalizations in GDMT-treated NYHA Class III HF patients. These effects were most pronounced in patients not treated with CRT.

Published
2015

43. Characterization of subgroups of heart failure patients with preserved ejection fraction with possible implications for prognosis and treatment response

Author

Kao, David P., primary, Lewsey, James D., additional, Anand, Inder S., additional, Massie, Barry M., additional, Zile, Michael R., additional, Carson, Peter E., additional, McKelvie, Robert S., additional, Komajda, Michel, additional, McMurray, John JV, additional, and Lindenfeld, JoAnn, additional

Published
2015
Full Text
View/download PDF

44. Baroreflex activation therapy for the treatment of heart failure with a reduced ejection fraction: safety and efficacy in patients with and without cardiac resynchronization therapy

Author

Zile, Michael R., primary, Abraham, William T., additional, Weaver, Fred A., additional, Butter, Christian, additional, Ducharme, Anique, additional, Halbach, Marcel, additional, Klug, Didier, additional, Lovett, Eric G., additional, Müller‐Ehmsen, Jochen, additional, Schafer, Jill E., additional, Senni, Michele, additional, Swarup, Vijay, additional, Wachter, Rolf, additional, and Little, William C., additional

Published
2015
Full Text
View/download PDF

46. Comparison of outcomes after hospitalization for worsening heart failure, myocardial infarction, and stroke in patients with heart failure and reduced and preserved ejection fraction

Author

Kristensen, Søren L., primary, Jhund, Pardeep S., additional, Køber, Lars, additional, Preiss, David, additional, Kjekshus, John, additional, McKelvie, Robert S., additional, Zile, Michael R., additional, Anand, Inder S., additional, Wikstrand, John, additional, Wedel, Hans, additional, Komajda, Michel, additional, Carson, Peter E., additional, Cleland, John G.F., additional, and McMurray, John J.V., additional

Published
2014
Full Text
View/download PDF

47. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial

Author

Jhund, Pardeep S., primary, Claggett, Brian, additional, Packer, Milton, additional, Zile, Michael R, additional, Voors, Adriaan A., additional, Pieske, Burkert, additional, Lefkowitz, Martin, additional, Shi, Victor, additional, Bransford, Toni, additional, McMurray, John J. V., additional, and Solomon, Scott D, additional

Published
2014
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results